State-of-the-Art Colorectal Cancer and Advanced Precancerous Lesion Screening: a Multitarget Stool DNA Test.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2025-01-01 DOI:10.7754/Clin.Lab.2024.240620

Lena Krammes, Hiba-Tun-Noor A Mahmood, Friederike M B Frondorf, Christian F Scholz, Patrick Becker, Srijana Maharjan, Ayfer E Sever, Santhi V Garapati, Anujan Balasubramaniam, Martin J Knabe, Moritz R Eidens, Matthias M Dollinger

{"title":"State-of-the-Art Colorectal Cancer and Advanced Precancerous Lesion Screening: a Multitarget Stool DNA Test.","authors":"Lena Krammes, Hiba-Tun-Noor A Mahmood, Friederike M B Frondorf, Christian F Scholz, Patrick Becker, Srijana Maharjan, Ayfer E Sever, Santhi V Garapati, Anujan Balasubramaniam, Martin J Knabe, Moritz R Eidens, Matthias M Dollinger","doi":"10.7754/Clin.Lab.2024.240620","DOIUrl":null,"url":null,"abstract":"Background: Colorectal cancer (CRC) claims 900,000 lives per year. Colonoscopy offers reliable detection, but with low patient adherence rates. To significantly reduce CRC incidence and mortality, a more convenient screening measure for advanced precancerous lesions (APL) and CRC is urgently needed.Methods: In this study, the clinical performance of a multitarget stool DNA (mt-sDNA) test combining fecal im-munochemical test (FIT) with the analysis of genetic biomarkers by real-time PCR was evaluated in a cohort of 208 subjects.Results: The mt-sDNA test showed a sensitivity of 84.2% for CRC (all stages) and 39.6% sensitivity for APL detection with a specificity of 91.5%. Within the APL group, high-grade dysplasia, characterized by the highest risk of further cancer progression, were detected with 75% sensitivity.Conclusions: The mt-sDNA test represents a significant advancement for non-invasive detection of APL and CRC and bears great potential to enhance CRC prevention, incidence, and mortality.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"71 1","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240620","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Colorectal cancer (CRC) claims 900,000 lives per year. Colonoscopy offers reliable detection, but with low patient adherence rates. To significantly reduce CRC incidence and mortality, a more convenient screening measure for advanced precancerous lesions (APL) and CRC is urgently needed.

Methods: In this study, the clinical performance of a multitarget stool DNA (mt-sDNA) test combining fecal im-munochemical test (FIT) with the analysis of genetic biomarkers by real-time PCR was evaluated in a cohort of 208 subjects.

Results: The mt-sDNA test showed a sensitivity of 84.2% for CRC (all stages) and 39.6% sensitivity for APL detection with a specificity of 91.5%. Within the APL group, high-grade dysplasia, characterized by the highest risk of further cancer progression, were detected with 75% sensitivity.

Conclusions: The mt-sDNA test represents a significant advancement for non-invasive detection of APL and CRC and bears great potential to enhance CRC prevention, incidence, and mortality.

查看原文本刊更多论文

最先进的结直肠癌和晚期癌前病变筛查：多靶点粪便DNA检测。

背景：结直肠癌（CRC）每年夺走90万人的生命。结肠镜检查提供了可靠的检测，但患者依从率较低。为了显著降低CRC的发病率和死亡率，迫切需要一种更便捷的晚期癌前病变（APL）和CRC的筛查手段。方法：本研究对208名受试者进行多靶点粪便DNA （mt-sDNA）检测，并结合粪便免疫化学测试（FIT）和实时荧光定量PCR分析遗传生物标志物。结果：mt-sDNA检测对CRC（所有分期）的敏感性为84.2%，对APL检测的敏感性为39.6%，特异性为91.5%。在APL组中，以癌症进一步进展的最高风险为特征的高度发育不良的检测灵敏度为75%。结论：mt-sDNA检测在无创性检测APL和CRC方面取得了重大进展，在提高CRC的预防、发病率和死亡率方面具有很大的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.